Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel
Open Access
- 1 August 1996
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 74 (4) , 502-507
- https://doi.org/10.1038/bjc.1996.393
Abstract
A panel of doxorubicin-resistant sublines of the human small-cell lung carcinoma cell line GLC4 displays decreasing DNA topoisomerase II alpha (TopoII alpha) mRNA levels with increasing resistance. In the present study we describe how this decrease may be regulated. No significant differences in TopoII alpha mRNA stability or gene arrangement were found, using mRNA slot-blotting and Southern blotting, in the most resistant cell line compared with the parental cell line. To investigate if TopoII alpha gene copy loss contributed to the mRNA decrease, fluorescence in situ hybridisation using a TopoII alpha-specific probe was performed. During doxorubicin resistance development, the composition of the population in each cell line shifted with increasing resistance, from a population in which most cells contain three TopoII alpha gene copies (GLC4) to a population in which most cells contain only two copies. A partial revertant of the most resistant cell line displayed a shift back to the original situation. We conclude that the TopoII alpha gene copy number decrease per cell line is in good agreement with the decreased TopoII alpha mRNA and protein levels, and TopoII activity levels in these cell lines which were described previously.Keywords
This publication has 35 references indexed in Scilit:
- Resistance‐associated factors in human small‐cell lung‐carcinoma GLC4 sub‐lines with increasing adriamycin resistanceInternational Journal of Cancer, 1995
- Mechanisms of MRP over‐expression in four human lung‐cancer cell lines and analysis of the MRP ampliconInternational Journal of Cancer, 1995
- Interphase cytogenetic analysis of erbB2 and topollα co‐amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situInternational Journal of Cancer, 1995
- Translocation (3;21)(q26;q22) in therapy-related myelodysplasia following drugs targeting DNA-topoisomerase II combined with alkylating agnets, and in myeloproliferative disorders undergoing spontaneous leukemic transformationCancer Genetics and Cytogenetics, 1994
- Discrete Localization of Different DNA Topoisomerases in HeLa and K562 Cell Nuclei and Subnuclear FractionsExperimental Cell Research, 1994
- Co-amplification of erbB2, topoisomerase II α and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20European Journal Of Cancer, 1993
- Characterization of a Topoisomerase II Gene Rearrangement in a Human Small-Cell Lung Cancer Cell LineJNCI Journal of the National Cancer Institute, 1992
- Quantification of inter‐ and intra‐nuclear variation of fluorescence in situ hybridization signalsCytometry, 1992
- Topoisomerase-targeting antitumor drugsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1989
- Nonproductive Rearrangement of DNA Topoisomerase I and II Genes: Correlation With Resistance to Topoisomerase InhibitorsJNCI Journal of the National Cancer Institute, 1989